<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05027191</url>
  </required_header>
  <id_info>
    <org_study_id>110-T</org_study_id>
    <nct_id>NCT05027191</nct_id>
  </id_info>
  <brief_title>Effect of Desflurane Versus Sevoflurane With Recent Bio-markers on Renal and Hepatic Functions</brief_title>
  <official_title>Evaluating the Effect of Desflurane Versus Sevoflurane With Recent Biomarkers of Renal and Hepatic Function in Laparoscopic Cholecystectomy Patients: A Prospective Randomized Double Blinded Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theodor Bilharz Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Theodor Bilharz Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studying the effects of both inhalational anesthetics desflurane and sevoflurane on hepatic&#xD;
      integrity and renal function, guided by recent blood and urine biomarkers in patients&#xD;
      undergoing laparoscopic cholecystectomy surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2018</start_date>
  <completion_date type="Actual">December 1, 2019</completion_date>
  <primary_completion_date type="Actual">November 20, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum Neutrophil gelatinase-associated lipocalin (NGAL)</measure>
    <time_frame>a change from baseline NGAL serum level at 6 hours</time_frame>
    <description>Renal Biomarker</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum Arginase</measure>
    <time_frame>Baseline, first hour, six hours, after 24 hours</time_frame>
    <description>Hepatic biomarker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum Cystatin-c</measure>
    <time_frame>Baseline, first hour, six hours, after 24 hours</time_frame>
    <description>Hepatic biomarker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urine Netrin-1</measure>
    <time_frame>Baseline, first hour, six hours, after 24 hours</time_frame>
    <description>Renal biomarker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urine Kidney Injury Molecule</measure>
    <time_frame>Baseline, first hour, six hours, after 24 hours</time_frame>
    <description>Renal biomarker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urine Interleukin-18</measure>
    <time_frame>Baseline, first hour, six hours, after 24 hours</time_frame>
    <description>cytokines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urine Alpha-Glutathione S-Transferase</measure>
    <time_frame>Baseline, first hour, six hours, after 24 hours</time_frame>
    <description>Liver biomarker</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">70</enrollment>
  <condition>Postoperative Complications</condition>
  <arm_group>
    <arm_group_label>Sevoflurane</arm_group_label>
    <description>This group will receive sevoflurane as the maintenance inhalational anesthetic.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Desflurane</arm_group_label>
    <description>This group will receive desflurane as the maintenance inhalational anesthetic.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Neutrophil Gelatinase-Associated Lipocalin (NGAL)</intervention_name>
    <description>The evaluation of inhalational anesthetics (desflurane and sevoflurane) on NGAL levels in laparoscopic cholecystectomy patients.</description>
    <arm_group_label>Desflurane</arm_group_label>
    <arm_group_label>Sevoflurane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desflurane</intervention_name>
    <description>Desflurane</description>
    <arm_group_label>Desflurane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Sevoflurane</description>
    <arm_group_label>Sevoflurane</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        After informed written consents have been taken, this study will be conducted on 70&#xD;
        patients scheduled for laparoscopic cholecystectomy. The patients will be randomly&#xD;
        allocated into two groups (a desflurane (D) group and a sevoflurane (S) group) using a&#xD;
        sealed envelope technique for each group.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. American Society of Anesthesiologists (ASA) Class: I&amp;II.&#xD;
&#xD;
          2. Elective laparoscopic cholecystectomy.&#xD;
&#xD;
          3. Age: 25-55 years.&#xD;
&#xD;
          4. Gender: Both male and female.&#xD;
&#xD;
          5. Body Mass Index (BMI): 18.5-24.9 km2-(Normal weight).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Extremes of age.&#xD;
&#xD;
          2. Abnormal hepatic function by alanine aminotransferase (ALT) and aspartate&#xD;
             aminotransferase (AST) values outside the normal range.&#xD;
&#xD;
          3. Abnormal renal function by blood urea nitrogen (BUN) and creatinine above the normal&#xD;
             ranges.&#xD;
&#xD;
          4. Hypertension, unstable angina pectoris or myocardial infarction within the last six&#xD;
             months.&#xD;
&#xD;
          5. Pregnancy and lactation.&#xD;
&#xD;
          6. Bronchial asthma.&#xD;
&#xD;
          7. Drug allergies.&#xD;
&#xD;
          8. Alcohol or drug addiction.&#xD;
&#xD;
          9. General anesthesia within the last three months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Khalda G Radwan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Theodor Bilharz Rsearch Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Theodor Bilharz Research Institute</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 11, 2019</study_first_submitted>
  <study_first_submitted_qc>August 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Theodor Bilharz Research Institute</investigator_affiliation>
    <investigator_full_name>khalda Galal Moustafa</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevoflurane</mesh_term>
    <mesh_term>Desflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

